Table of Content

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 17
1.3.1 MARKETS COVERED 17
1.3.2 YEARS CONSIDERED FOR THE STUDY 18
1.4 CURRENCY 18
1.5 STAKEHOLDERS 18

2 RESEARCH METHODOLOGY 19
2.1 RESEARCH DATA 19
2.1.1 SECONDARY DATA 21
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY DATA 22
2.1.2.1 Key data from primary sources 23
2.2 MARKET SIZE ESTIMATION 24
2.2.1 PRODUCT-BASED MARKET ESTIMATION 25
2.2.2 PRIMARY RESEARCH VALIDATION 26
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 27
2.4 RESEARCH LIMITATIONS AND ASSUMPTIONS 28
2.4.1 LIMITATIONS 28
2.4.2 ASSUMPTIONS 28

3 EXECUTIVE SUMMARY 29

4 PREMIUM INSIGHTS 33
4.1 LYMPHEDEMA DIAGNOSTICS: MARKET OVERVIEW 33
4.2 REGIONAL ANALYSIS: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE (2019) 34
4.3 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019 VS. 2024 (USD MILLION) 35
4.4 NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY TYPE,
2019 VS. 2024 (USD MILLION) 36
4.5 LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY 37

5 MARKET OVERVIEW 38
5.1 INTRODUCTION 38
5.2 MARKET DYNAMICS 38
5.2.1 DRIVERS 39
5.2.1.1 Growing global prevalence of lymphedema 39
5.2.1.2 Growing global prevalence of cancer 39
5.2.1.3 Technological advancements and adoption of newer diagnostic modalities 39
5.2.1.4 Increasing investments, funds, and grants by public-private organizations 41
5.2.2 RESTRAINTS 42
5.2.2.1 High cost of diagnostic imaging systems 42
5.2.2.2 Short half-life of radiopharmaceuticals 42
5.2.2.3 Limited supply of helium 42
5.2.2.4 Increasing adoption of refurbished diagnostic imaging systems 43
5.2.3 OPPORTUNITIES 43
5.2.3.1 Emerging countries 43
5.2.4 CHALLENGES 43
5.2.4.1 Hospital budget cuts 43

6 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 45
6.1 INTRODUCTION 46
6.2 LYMPHOSCINTIGRAPHY 47
6.2.1 LYMPHOSCINTIGRAPHY IS RAPIDLY DEVELOPING TO BE THE FIRST-LINE IMAGING MODALITY FOR LYMPHEDEMA DIAGNOSTICS 47
6.3 MAGNETIC RESONANCE IMAGING 48
6.3.1 MAGNETIC RESONANCE IMAGING FINDS MAJOR APPLICATIONS IN LYMPHEDEMA TREATMENT PLANNING 48
6.4 ULTRASOUND IMAGING 50
6.4.1 ULTRASOUND IMAGING HAS THE POTENTIAL TO DETERMINE TISSUE CHANGES CONSISTENT WITH DIFFERENT STAGES OF LYMPHEDEMA 50
6.5 COMPUTED TOMOGRAPHY 51
6.5.1 HIGH COST OF COMPUTED TOMOGRAPHY TO LIMIT MARKET GROWTH 51
6.6 X-RAY LYMPHOGRAPHY 52
6.6.1 INVASIVE NATURE & RISK OF RADIATION EXPOSURE ARE EXPECTED TO HAMPER MARKET GROWTH 52
6.7 BIOIMPEDANCE ANALYSIS 53
6.7.1 LACK OF AWARENESS ABOUT BIOIMPEDANCE ANALYSIS IS LIMITING THE GROWTH OF THIS SEGMENT 53
6.8 NEAR-INFRARED FLUORESCENCE IMAGING 55
6.8.1 ICG LYMPHOGRAPHY 56
6.8.1.1 ICG lymphography offers a powerful tool for efficiently diagnosing various stages of lymphedema 56
6.8.2 FLUORESCEIN SODIUM MICROLYMPHANGIOGRAPHY 58
6.8.2.1 Fluorescein sodium microlymphangiography is limited to visualizing only initial capillaries 58
?

7 LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 59
7.1 INTRODUCTION 60
7.2 CANCER 60
7.2.1 ONE IN THREE CANCER-TREATED PATIENTS DEVELOP LYMPHEDEMA 60
7.3 INFLAMMATORY DISEASES 61
7.3.1 GROWING PREVALENCE OF INFLAMMATORY CONDITIONS
TO DRIVE MARKET GROWTH 61
7.4 CARDIOVASCULAR DISEASE 62
7.4.1 GROWING AWARENESS ABOUT EARLY DISEASE DIAGNOSIS
TO DRIVE THE ADOPTION OF LYMPHEDEMA DIAGNOSTIC TOOLS 62
7.5 OTHER DISEASES 63

8 LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 64
8.1 INTRODUCTION 65
8.2 HOSPITALS 65
8.2.1 THE LARGE NUMBER OF LYMPHEDEMA DIAGNOSTIC PROCEDURES PERFORMED IN HOSPITALS TO DRIVE MARKET GROWTH 65
8.3 DIAGNOSTIC CENTERS 66
8.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH 66
8.4 RESEARCH & ACADEMIC INSTITUTES 67
8.4.1 BUDGETARY RESTRICTIONS OF RESEARCHERS ARE LIMITING THE ADOPTION OF HIGH-END LYMPHEDEMA DIAGNOSTIC TECHNOLOGIES 67
8.5 OTHER END USERS 68

9 LYMPHEDEMA DIAGNOSTICS MARKET, BY REGION 69
9.1 INTRODUCTION 70
9.2 NORTH AMERICA 71
9.2.1 US 73
9.2.1.1 The US dominated the North American market in 2018 73
9.2.2 CANADA 75
9.2.2.1 Dearth of radiologists is restricting market growth in Canada 75
9.3 EUROPE 77
9.3.1 GERMANY 81
9.3.1.1 Germany accounts for the largest share of the European market 81
9.3.2 FRANCE 82
9.3.2.1 Uncertainties with regard to the pricing strategy of diagnostic companies to limit market growth in France to a certain extent 82
9.3.3 UK 84
9.3.3.1 Rising diagnostic imaging procedural volumes indicate strong growth in the UK market 84
9.3.4 ROE 86
?
9.4 ASIA PACIFIC 88
9.4.1 CHINA 92
9.4.1.1 Rising disease incidence, increasing procedural volumes, and growth in the geriatric population have contributed to market growth in China 92
9.4.2 JAPAN 94
9.4.2.1 Japan’s well-established and well-equipped healthcare system ensures demand for and easy access to diagnostic imaging 94
9.4.3 INDIA 96
9.4.3.1 Growing incidence of lymphatic filariasis is a key contributor to market growth 96
9.4.4 ROAPAC 98
9.5 REST OF THE WORLD 99
9.5.1 LATIN AMERICA 101
9.5.1.1 Latin America holds the largest share of the RoW market 101
9.5.2 MIDDLE EAST & AFRICA 103
9.5.2.1 Growing geriatric population & disease prevalence are driving growth in MEA 103

10 COMPETITIVE LANDSCAPE 106
10.1 INTRODUCTION 106
10.2 RANKING OF PLAYERS, 2018 106
10.3 COMPETITIVE SCENARIO 107
10.4 VENDOR DIVE OVERVIEW 108
10.5 VENDOR INCLUSION CRITERIA 109
10.6 VENDOR DIVE 109
10.6.1 VISIONARY LEADERS 109
10.6.2 INNOVATORS 109
10.6.3 DYNAMIC DIFFERENTIATORS 109
10.6.4 EMERGING COMPANIES 109

11 COMPANY PROFILES 111
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 GE HEALTHCARE 111
11.2 SIEMENS HEALTHINEERS (A SUBSIDIARY OF SIEMENS GROUP) 115
11.3 PHILIPS 121
11.4 CANON, INC. 127
11.5 SHIMADZU CORPORATION 132
11.6 STRYKER CORPORATION 135
11.7 FLUOPTICS 137
11.8 UNITED IMAGING HEALTHCARE CO., LTD. 138
11.9 HITACHI, LTD. 139
11.10 ESAOTE SPA 143
11.11 NEUSOFT CORPORATION 146
11.12 MINDRAY MEDICAL INTERNATIONAL LIMITED (A SUBSIDIARY OF
EXCELSIOR UNION, LTD.) 148
11.13 MITAKA USA, INC. 150
11.14 CURADEL, LLC 151
11.15 IMPEDIMED LIMITED 152
11.16 OTHER COMPANIES 153
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX 158
12.1 DISCUSSION GUIDE 158
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 162
12.3 AVAILABLE CUSTOMIZATIONS 164
12.4 RELATED REPORTS 164
12.5 AUTHOR DETAILS 165



List of Figures



FIGURE 1 LYMPHEDEMA DIAGNOSTICS MARKET: RESEARCH METHODOLOGY STEPS 19
FIGURE 2 RESEARCH DESIGN 20
FIGURE 3 BREAKDOWN OF PRIMARIES: GLOBAL LYMPHEDEMA DIAGNOSTICS MARKET 23
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 24
FIGURE 5 MARKET SIZE ESTIMATION: LYMPHEDEMA DIAGNOSTICS MARKET 26
FIGURE 6 DATA TRIANGULATION METHODOLOGY 27
FIGURE 7 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2019 VS. 2024 (USD MILLION) 29
FIGURE 8 GEOGRAPHIC ANALYSIS: LYMPHEDEMA DIAGNOSTICS MARKET BY DISEASE TYPE, 2019 30
FIGURE 9 LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2019 VS. 2024 31
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE LYMPHEDEMA DIAGNOSTICS MARKET 32
FIGURE 11 RISING PREVALENCE OF LYMPHEDEMA?A MAJOR FACTOR DRIVING THE MARKET FOR LYMPHEDEMA DIAGNOSTICS 33
FIGURE 12 NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE OF THE LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, IN 2019 34
FIGURE 13 NEAR-INFRARED FLUORESCENCE IMAGING TO REGISTER THE HIGHEST GROWTH IN THE LYMPHEDEMA DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 35
FIGURE 14 ICG LYMPHOGRAPHY SEGMENT WILL CONTINUE TO DOMINATE THE NEAR-INFRARED FLUORESCENCE IMAGING MARKET IN 2024 36
FIGURE 15 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 37
FIGURE 16 LYMPHEDEMA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 38
FIGURE 17 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET SNAPSHOT 71
FIGURE 18 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET SNAPSHOT 78
FIGURE 19 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET SNAPSHOT 89
FIGURE 20 GE HEALTHCARE HELD THE LEADING POSITION IN THE LYMPHEDEMA DIAGNOSTICS MARKET IN 2018 106
FIGURE 21 LYMPHEDEMA DIAGNOSTICS MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2018 110
FIGURE 22 GE HEALTHCARE: COMPANY SNAPSHOT 111
FIGURE 23 SIEMENS AG: COMPANY SNAPSHOT 115
FIGURE 24 PHILIPS: COMPANY SNAPSHOT 121
FIGURE 25 CANON, INC.: COMPANY SNAPSHOT 127
FIGURE 26 SHIMADZU CORPORATION: COMPANY SNAPSHOT 132
FIGURE 27 STRYKER CORPORATION: COMPANY SNAPSHOT 135
FIGURE 28 HITACHI, LTD.: COMPANY SNAPSHOT 139
FIGURE 29 NEUSOFT CORPORATION: COMPANY SNAPSHOT 146
FIGURE 30 IMPEDIMED LIMITED: COMPANY SNAPSHOT 152

 

List of Tables



TABLE 1 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTIC IMAGING SYSTEMS 40
TABLE 2 KEY INVESTMENTS BY GOVERNMENT BODIES IN
THE DIAGNOSTIC IMAGING MARKET 41
TABLE 3 LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 46
TABLE 4 COMPARISON OF DIAGNOSTIC IMAGING TESTS FOR LYMPHEDEMA 46
TABLE 5 LYMPHOSCINTIGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION) 47
TABLE 6 LYMPHOSCINTIGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 48
TABLE 7 MAGNETIC RESONANCE IMAGING MARKET, BY REGION 2017–2024 (USD MILLION) 49
TABLE 8 MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY 2017–2024 (USD MILLION) 49
TABLE 9 ULTRASOUND IMAGING MARKET, BY REGION, 2017–2024 (USD MILLION) 50
TABLE 10 ULTRASOUND IMAGING MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 51
TABLE 11 COMPUTED TOMOGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION) 51
TABLE 12 COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 52
TABLE 13 X-RAY LYMPHOGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION) 52
TABLE 14 X-RAY LYMPHOGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 53
TABLE 15 BIOIMPEDANCE ANALYSIS MARKET, BY REGION, 2017–2024 (USD MILLION) 54
TABLE 16 BIOIMPEDANCE ANALYSIS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 54
TABLE 17 NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY TYPE 2017–2024 (USD MILLION) 55
TABLE 18 NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY REGION 2017–2024 (USD MILLION) 55
TABLE 19 NEAR-INFRARED FLUORESCENCE IMAGING MARKET, BY COUNTRY 2017–2024 (USD MILLION) 56
TABLE 20 ICG LYMPHOGRAPHY MARKET, BY REGION, 2017–2024 (USD MILLION) 57
TABLE 21 ICG LYMPHOGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 57
TABLE 22 FLUORESCEIN SODIUM MICROLYMPHANGIOGRAPHY MARKET, BY REGION 2017–2024 (USD MILLION) 58
TABLE 23 FLUORESCEIN SODIUM MICROLYMPHANGIOGRAPHY MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 58
TABLE 24 LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 60
TABLE 25 LYMPHEDEMA DIAGNOSTICS MARKET FOR CANCER, BY REGION 2017–2024 (USD MILLION) 61
TABLE 26 LYMPHEDEMA DIAGNOSTICS MARKET FOR INFLAMMATORY DISEASES BY REGION, 2017–2024 (USD MILLION) 61
TABLE 27 LYMPHEDEMA DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASE BY REGION, 2017–2024 (USD MILLION) 62
TABLE 28 LYMPHEDEMA DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION 2017–2024 (USD MILLION) 63
TABLE 29 LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION) 65
TABLE 30 LYMPHEDEMA DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION 2017–2024 (USD MILLION) 66
TABLE 31 LYMPHEDEMA DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2017–2024 (USD MILLION) 67
TABLE 32 LYMPHEDEMA DIAGNOSTICS MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2017–2024 (USD MILLION) 68
TABLE 33 LYMPHEDEMA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2017–2024 (USD MILLION) 68
TABLE 34 LYMPHEDEMA DIAGNOSTICS MARKET, BY REGION, 2017–2024 (USD MILLION) 70
TABLE 35 LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 70
TABLE 36 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 72
TABLE 37 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 72
TABLE 38 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 72
TABLE 39 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 73
TABLE 40 NORTH AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 73
TABLE 41 US: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 74
TABLE 42 US: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 74
TABLE 43 US: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 75
TABLE 44 US: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 75
TABLE 45 CANADA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 76
TABLE 46 CANADA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 76
TABLE 47 CANADA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 77
TABLE 48 CANADA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 77
TABLE 49 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 79
TABLE 50 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 79
TABLE 51 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 80
TABLE 52 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 80
TABLE 53 EUROPE: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 80
TABLE 54 GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 81
TABLE 55 GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 81
TABLE 56 GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 82
TABLE 57 GERMANY: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 82
TABLE 58 FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 83
TABLE 59 FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 83
TABLE 60 FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 84
TABLE 61 FRANCE: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 84
TABLE 62 UK: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 85
TABLE 63 UK: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 85
TABLE 64 UK: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 86
TABLE 65 UK: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 86
TABLE 66 ROE: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 87
TABLE 67 ROE: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 87
TABLE 68 ROE: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 87
TABLE 69 ROE: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 88
TABLE 70 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 90
TABLE 71 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 90
TABLE 72 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 91
TABLE 73 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 91
TABLE 74 ASIA PACIFIC: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 91
TABLE 75 CHINA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 92
TABLE 76 CHINA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 93
TABLE 77 CHINA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 93
TABLE 78 CHINA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 93
TABLE 79 JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 94
TABLE 80 JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 95
TABLE 81 JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 95
TABLE 82 JAPAN: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 95
TABLE 83 INDIA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 96
TABLE 84 INDIA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 97
TABLE 85 INDIA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 97
TABLE 86 INDIA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 97
TABLE 87 ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 98
TABLE 88 ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 98
TABLE 89 ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 99
TABLE 90 ROAPAC: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 99
TABLE 91 ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY REGION 2017–2024 (USD MILLION) 100
TABLE 92 ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 100
TABLE 93 ROW: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 100
TABLE 94 ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 101
TABLE 95 ROW: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 101
TABLE 96 LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 102
TABLE 97 LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 102
TABLE 98 LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE 2017–2024 (USD MILLION) 103
TABLE 99 LATIN AMERICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 103
TABLE 100 MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 104
TABLE 101 MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET FOR NEAR-INFRARED FLUORESCENCE IMAGING, BY TYPE, 2017–2024 (USD MILLION) 104
TABLE 102 MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY DISEASE TYPE, 2017–2024 (USD MILLION) 105
TABLE 103 MIDDLE EAST & AFRICA: LYMPHEDEMA DIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION) 105
TABLE 104 PRODUCT LAUNCHES, ENHANCEMENTS, & APPROVALS 107
TABLE 105 PARTNERSHIPS, COLLABORATIONS, & AGREEMENTS 107
TABLE 106 ACQUISITIONS 108
TABLE 107 EXPANSIONS 108